Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as dose modifications and safety for the novel agents imetelstat and luspatercept.#MDS targetedonc.com/view/brunner-d…

Been seeing some big darkpool on $GERN the past few trading sessions. No surpise they shoved It down to grab shares before J-code goes into effect for the drug RYTELO (imetelstat) This is a big win for patients as insurance enbable providers for processing claims

Some major AH volume came in on $GERN 🥁

The EU Medicines Agency has recommended imetelstat for the treatment of patients with transfusion-dependent anemia due to very low–, low- or intermediate-risk #MDS, based on findings from the phase 3 IMerge trial. #ASH24 #hematology Read more: onclive.com/view/chmp-offe…

A positive opinion issued by EU Medicines Agency recommending the approval of imetelstat for the treatment of select adult patients with transfusion-dependent anemia due to very low–, low- or intermediate-risk MDS. #MedTwitter #Oncology Read: onclive.com/view/chmp-offe…

Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis ASH Mount Sinai Tisch Cancer Center Icahn School of Medicine at Mount Sinai #myelofibrosis onclive.com/view/imetelsta…

Brand new review by Rafael Madero Marroquín Joseph Cannova and Toyosi Odenike on imetelstat in lower-risk MDS! ashpublications.org/bloodadvances/…

Honoured to review updates in MDS and AML. Menin mania, long-term outcomes with 1L luspatercept, imetelstat, and so much more! MD Anderson Cancer Center #MDSsm #AMLsm

$GERN “ positioned for profitability without additional financing”. Kudos to some small/mid caps for reaching this milestones despite hostile market environment.

$gern darkest before the dawn. #Conviction

Needham $7 pt $gern

$gern oversold

$gern

Covered Call Alert: GERON $GERN returning up to 20.97% through 20-Jun-2025 ideas.quantcha.com/?p=150478

$gern

$gern

3rd qrt 2024, first sales, no J-code $28 mil 4th qtr 2024, guidance, no J-code $45-46 mill 1st qtr 2025, sales ramping, and now a new J-code $??? full year 2025, continued market penetration + existing patients on Rytelo $??? 2026 USA + EU sales ?? 2027 MF approval ?

Ce magnific!